Jennifer R. Brown
A5016570475- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Glycosylation and Glycoproteins Research
- T-cell and Retrovirus Studies
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
- Gastrointestinal Tumor Research and Treatment
- RNA modifications and cancer
- Galectins and Cancer Biology
- Cancer-related gene regulation
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
Dana-Farber Cancer Institute
2016-2025
Harvard University
2016-2025
Mayo Clinic
2017-2024
Brigham and Women's Hospital
2015-2024
Cancer Institute (WIA)
2017-2024
Dana-Farber Brigham Cancer Center
2003-2024
Universitat de Barcelona
2023
Broad Institute
2012-2023
Boston University
2013-2023
TriNetX (United States)
2023
New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, protein central to the survival CLL cells.
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy adverse cytogenetic abnormalities are associated poor outcome. We evaluated the efficacy ibrutinib, covalent inhibitor Bruton's tyrosine kinase, in at risk for
The somatic genetic basis of chronic lymphocytic leukemia, a common and clinically heterogeneous leukemia occurring in adults, remains poorly understood.
Ibrutinib has been approved by the Food and Drug Administration for treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but not compared chemoimmunotherapy. We conducted a phase 3 trial to evaluate efficacy ibrutinib, either alone or in combination rituximab, relative
Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment chronic lymphocytic leukemia (CLL). However, also irreversibly inhibits alternative targets, which potentially compromises its index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that specifically designed to improve on safety and efficacy first-generation inhibitors.In this uncontrolled, phase 1-2, multicenter study, we administered...
BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits and related proteins BCL-x(l) BCL-w, potently inducing apoptosis CLL cells in vitro. A phase I trial patients with was conducted to evaluate the safety, pharmacokinetics, biologic activity oral navitoclax.Twenty-nine relapsed or refractory received daily for 14 days (10, 110, 200, 250 mg/d; n = 15) 21 (125, 250, 300 14) each 21-day cycle. Dose escalation...
Antiapoptotic B cell leukemia/lymphoma 2 (BCL2) family proteins are expressed in many cancers, but the circumstances under which these necessary for tumor maintenance poorly understood. We exploited a novel functional assay that uses BCL2 homology domain 3 (BH3) peptides to predict dependence on antiapoptotic proteins, strategy we call BH3 profiling. profiling accurately predicts sensitivity antagonist ABT-737 primary chronic lymphocytic leukemia (CLL) cells. also distinguishes myeloid...
Abstract Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment patients with chronic lymphocytic leukemia (CLL) or small lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy single‐agent ibrutinib over ofatumumab relapsed/refractory CLL/SLL, including those high‐risk features. Here we report final analysis from median follow‐up on 65.3 months (range, 0.3‐71.6) arm. Median progression‐free survival (PFS)...
The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the type I cytokine receptor subunit CRLF2 functional screen B-ALL-derived mRNA transcripts that can substitute IL3 signaling. demonstrate is overexpressed approximately 15% adult and high-risk pediatric B-ALL MLL, TCF3, TEL, BCR/ABL rearrangements, but not these rearrangements or other lymphoid malignancies. overexpression result...
Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely mutations in BTK and related pathway molecules. Using whole-exome deep-targeted sequencing, we dissect evolution of resistance serial samples from five chronic lymphocytic leukaemia patients. In two patients, detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit an expansion clones harbouring del(8p) with additional driver (EP300, MLL2 EIF2A), one patient...